Which has better earnings & valuation, CYRX or IMUX?

CryoPort has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $176.18M 4.72 $78.30M $1.35 12.22 Immunic N/A N/A -$97.17M -$5.58 N/A

Is CYRX or IMUX more profitable?

CryoPort has a net margin of 41.57% compared to Immunic's net margin of 0.00%. CryoPort's return on equity of -7.92% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets CryoPort 41.57% -7.92% -4.79% Immunic N/A -220.75% -132.04%

Is ALLO or IMUX more profitable?

Allogene Therapeutics' return on equity of -56.45% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Immunic N/A -220.75% -132.04%

Does the media prefer ALLO or IMUX?

In the previous week, Allogene Therapeutics and Allogene Therapeutics both had 4 articles in the media. Immunic's average media sentiment score of 0.73 beat Allogene Therapeutics' score of 0.53 indicating that Immunic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, IMUX or DSGN?

Design Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$5.58 N/A Design Therapeutics N/A N/A -$69.79M -$1.20 N/A

Is IMUX or DSGN more profitable?

Design Therapeutics' return on equity of -33.07% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -220.75% -132.04% Design Therapeutics N/A -33.07% -31.29%

Does the media refer more to IMUX or DSGN?

In the previous week, Immunic had 2 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Immunic and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat Immunic's score of 0.73 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, SLDB or IMUX?

Solid Biosciences is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.95 N/A Immunic N/A N/A -$97.17M -$5.58 N/A

Is SLDB or IMUX more profitable?

Solid Biosciences' return on equity of -73.42% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -73.42% -61.13% Immunic N/A -220.75% -132.04%

Does the media prefer SLDB or IMUX?

In the previous week, Solid Biosciences and Solid Biosciences both had 4 articles in the media. Immunic's average media sentiment score of 0.73 beat Solid Biosciences' score of 0.72 indicating that Immunic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate IMUX or AVTE?

Immunic presently has a consensus price target of $47.57, suggesting a potential upside of 235.72%. Given Immunic's stronger consensus rating and higher possible upside, equities research analysts plainly believe Immunic is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunic 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.00 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, IMUX or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$5.58 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is IMUX or AVTE more profitable?

Aerovate Therapeutics' return on equity of -90.19% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -220.75% -132.04% Aerovate Therapeutics N/A -90.19% -77.47%

Immunic (IMUX) Competitors

$14.17 -0.47 (-3.21%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$14.06 -0.11 (-0.78%)

As of 06/3/2026 07:30 PM Eastern

Compare

IMUX vs. CYRX, ALLO, DSGN, SLDB, and AVTE

Should you buy Immunic stock or one of its competitors? MarketBeat compares Immunic with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunic include CryoPort (CYRX), Allogene Therapeutics (ALLO), Design Therapeutics (DSGN), Solid Biosciences (SLDB), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry.

How does Immunic compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Immunic (NASDAQ:IMUX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

CryoPort currently has a consensus price target of $15.31, suggesting a potential downside of 7.20%. Immunic has a consensus price target of $47.57, suggesting a potential upside of 235.72%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

CryoPort has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, Immunic has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

CryoPort has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.72	$78.30M	$1.35	12.22
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

CryoPort has a net margin of 41.57% compared to Immunic's net margin of 0.00%. CryoPort's return on equity of -7.92% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Immunic	N/A	-220.75%	-132.04%

92.9% of CryoPort shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 10.0% of CryoPort shares are held by company insiders. Comparatively, 14.0% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Immunic had 3 more articles in the media than CryoPort. MarketBeat recorded 4 mentions for Immunic and 1 mentions for CryoPort. CryoPort's average media sentiment score of 1.89 beat Immunic's score of 0.73 indicating that CryoPort is being referred to more favorably in the media.

Company	Overall Sentiment
CryoPort	Very Positive
Immunic	Positive

Summary

CryoPort beats Immunic on 11 of the 16 factors compared between the two stocks.

How does Immunic compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by insiders. Comparatively, 14.0% of Immunic shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Allogene Therapeutics' return on equity of -56.45% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Immunic	N/A	-220.75%	-132.04%

In the previous week, Allogene Therapeutics and Allogene Therapeutics both had 4 articles in the media. Immunic's average media sentiment score of 0.73 beat Allogene Therapeutics' score of 0.53 indicating that Immunic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunic	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunic has lower revenue, but higher earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	34,515.00	-$190.89M	-$0.77	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

Allogene Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Immunic has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market.

Allogene Therapeutics currently has a consensus price target of $8.52, suggesting a potential upside of 326.11%. Immunic has a consensus price target of $47.57, suggesting a potential upside of 235.72%. Given Allogene Therapeutics' higher possible upside, equities analysts clearly believe Allogene Therapeutics is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Allogene Therapeutics and Immunic tied by winning 7 of the 14 factors compared between the two stocks.

How does Immunic compare to Design Therapeutics?

Immunic (NASDAQ:IMUX) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Design Therapeutics' return on equity of -33.07% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-220.75%	-132.04%
Design Therapeutics	N/A	-33.07%	-31.29%

In the previous week, Immunic had 2 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Immunic and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat Immunic's score of 0.73 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

51.8% of Immunic shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 14.0% of Immunic shares are held by company insiders. Comparatively, 17.1% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Immunic has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

Immunic presently has a consensus price target of $47.57, indicating a potential upside of 235.72%. Design Therapeutics has a consensus price target of $16.50, indicating a potential upside of 58.05%. Given Immunic's stronger consensus rating and higher possible upside, analysts plainly believe Immunic is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Design Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Summary

Design Therapeutics beats Immunic on 8 of the 13 factors compared between the two stocks.

How does Immunic compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

Solid Biosciences currently has a consensus price target of $16.82, indicating a potential upside of 145.52%. Immunic has a consensus price target of $47.57, indicating a potential upside of 235.72%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

Solid Biosciences is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

In the previous week, Solid Biosciences and Solid Biosciences both had 4 articles in the media. Immunic's average media sentiment score of 0.73 beat Solid Biosciences' score of 0.72 indicating that Immunic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunic	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences' return on equity of -73.42% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Immunic	N/A	-220.75%	-132.04%

Solid Biosciences has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market. Comparatively, Immunic has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by insiders. Comparatively, 14.0% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Immunic beats Solid Biosciences on 7 of the 13 factors compared between the two stocks.

How does Immunic compare to Aerovate Therapeutics?

Immunic (NASDAQ:IMUX) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Immunic presently has a consensus price target of $47.57, suggesting a potential upside of 235.72%. Given Immunic's stronger consensus rating and higher possible upside, equities research analysts plainly believe Immunic is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Immunic has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

In the previous week, Immunic had 4 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 4 mentions for Immunic and 0 mentions for Aerovate Therapeutics. Immunic's average media sentiment score of 0.73 beat Aerovate Therapeutics' score of 0.67 indicating that Immunic is being referred to more favorably in the media.

Company	Overall Sentiment
Immunic	Positive
Aerovate Therapeutics	Positive

Aerovate Therapeutics' return on equity of -90.19% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-220.75%	-132.04%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

51.8% of Immunic shares are held by institutional investors. 14.0% of Immunic shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Summary

Immunic beats Aerovate Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Immunic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMUX vs. The Competition

Export

Metric	Immunic	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$199.42M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-2.54	17.78	22.39	24.18
Price / Sales	N/A	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	-25.76	6.63	9.84	6.72
Net Income	-$97.17M	$24.20M	$3.57B	$337.19M
7 Day Performance	-5.34%	-4.39%	-2.46%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	82.84%	45.50%	26.49%	33.10%

Immunic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMUX Immunic	3.1099 of 5 stars	$14.17 -3.2%	$47.57 +235.7%	+94.0%	$199.42M	N/A	N/A	70
CYRX CryoPort	3.6007 of 5 stars	$14.00 flat	$14.69 +4.9%	+182.5%	$705.60M	$176.18M	10.37	1,186	Positive News Analyst Forecast
ALLO Allogene Therapeutics	2.5785 of 5 stars	$2.00 flat	$8.52 +326.1%	+48.1%	$690.30M	$20K	N/A	310	Gap Down
DSGN Design Therapeutics	2.7627 of 5 stars	$10.97 flat	$16.50 +50.4%	+160.3%	$685.19M	N/A	N/A	40
SLDB Solid Biosciences	2.7909 of 5 stars	$6.62 flat	$16.36 +147.2%	+95.7%	$651.74M	N/A	N/A	100	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMUX) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunic (IMUX) Competitors

IMUX vs. CYRX, ALLO, DSGN, SLDB, and AVTE

How does Immunic compare to CryoPort?

Summary

How does Immunic compare to Allogene Therapeutics?

Summary

How does Immunic compare to Design Therapeutics?

Summary

How does Immunic compare to Solid Biosciences?

Summary

How does Immunic compare to Aerovate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX vs. The Competition

Immunic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunic (IMUX) Competitors

IMUX vs. CYRX, ALLO, DSGN, SLDB, and AVTE

How does Immunic compare to CryoPort?

Do analysts prefer CYRX or IMUX?

Which has more volatility and risk, CYRX or IMUX?

Which has better earnings & valuation, CYRX or IMUX?

Is CYRX or IMUX more profitable?

Do insiders & institutionals have more ownership in CYRX or IMUX?

Does the media favor CYRX or IMUX?

Summary

How does Immunic compare to Allogene Therapeutics?

Do institutionals & insiders hold more shares of ALLO or IMUX?

Is ALLO or IMUX more profitable?

Does the media prefer ALLO or IMUX?

Which has better valuation and earnings, ALLO or IMUX?

Which has more risk and volatility, ALLO or IMUX?

Do analysts prefer ALLO or IMUX?

Summary

How does Immunic compare to Design Therapeutics?

Is IMUX or DSGN more profitable?

Does the media refer more to IMUX or DSGN?

Do insiders and institutionals believe in IMUX or DSGN?

Which has more risk & volatility, IMUX or DSGN?

Do analysts prefer IMUX or DSGN?

Which has better earnings and valuation, IMUX or DSGN?

Summary

How does Immunic compare to Solid Biosciences?

Do analysts recommend SLDB or IMUX?

Which has stronger valuation and earnings, SLDB or IMUX?

Does the media prefer SLDB or IMUX?

Is SLDB or IMUX more profitable?

Which has more volatility & risk, SLDB or IMUX?

Do institutionals and insiders believe in SLDB or IMUX?

Summary

How does Immunic compare to Aerovate Therapeutics?

Do analysts rate IMUX or AVTE?

Which has more risk & volatility, IMUX or AVTE?

Does the media refer more to IMUX or AVTE?

Is IMUX or AVTE more profitable?

Do institutionals & insiders have more ownership in IMUX or AVTE?

Which has better earnings and valuation, IMUX or AVTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX vs. The Competition

Immunic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools